Biomarkers on prognosis and response to treatment in breast cancer;Biomarcadores en el pronóstico y respuesta al tratamiento en cáncer mamario

Gaceta Medica de Mexico

Volumn 138, Issue 1, 2002, Pages 15-24

  Gerson, Raquel ^a   Serrano, Alberto ^a   Villalobos, Alberto ^a   Sánchez Forgach, Ernesto ^a   Sánchez Basurto, Carlos ^a   Murillo, Ángel ^a   Ortiz Hidalgo, Carlos ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Biomarkers; Breast cancer; Prognostic factors; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

ADULT; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 0036190289     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Breast cancer
2. Approaches to breast cancer staging
3. Predicción del fenotipo metastático del cáncer mamario con los marcadores histológicos tumorales
4. Neu-protein overexpression in breast cancer association between comedo-type ductal carcinoma in situ and limited prognostic value, in stage II breast cancer
5. Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein expression compared with epidermal growth factor receptor DNA policy and conventional pathologic features
6. Amplification of a novel c-erbB-2 related gene in a human mammary carcinoma
7. p53: The challenge of linking basic science and patient management
8. p53 and ATM: Tumor supressor genes that have an impact on therapeutic responses
9. Tumor associated angiogenesis: Mechanisms, clinical implications, and the therapeutic strategies
10. Regulators of angiogenesis
11. The relationship of tumor angiogenesis and metastasis with emphasis on invasive breast carcinoma
12. Breast cancer increases initiation of angiogenesis without accelerating neovessel growth rate
13. The HER-2neu oncogen in breast cancer: Prognostic factor, predictive factor and target for therapy
14. Prognostic factors for invasive breast cancer
15. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
16. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node negative breast carcinoma
17. Biologic markers of breast cancer prognosis
18. Amplification of c-erbB-2 and aggresive human breast tumors
19. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
20. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy
21. Prognostic significance of progesteron receptor levels in estrogen receptor positive in patients with metastatic breast cancer treated with tamoxifen
22. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
23. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/C-neu protein
24. Efficacy and safety of herceptin (Humanized anti-her-2 antibody) as a single agent in 222 women with HER-2 overexpression who relapsed following chemotherapy for metastatic breast cancer
25. Addition of herceptin (Humanized anti-HER-2 antibody) to first line chemotherapy for HER-2 overexpressing metastatic breast cancer markedly increases anticancer activity
26. Mutations in the p53 gene occur in diverse human tumor types
27. Prognostic significance of vascular endothelial growth factor protein in node negative breast cancer
28. Mutations in the p53 gene occur in diverse human tumor types
29. Frequency of p53 mutations in breast carcinoma from ashkenazi jewish carriers of BRCA-1 mutations
30. Reduced MLHI expression in breast tumors after primary chemotherapy predicts disease free survival
31. Control of angiogenesis in fibroblasts by p53 regulation of thrompospondin-1
32. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: Analysis of 439 patients
33. Correlation between steroid hormone receptors and prognostic factors in human breast cancer
34. Estrogen receptor and the natural course of breast cancer
35. Progesteron and estrogen receptors as prognostic variables in breast cancer
36. Association between steroid hormone receptor status and disease free survival interval in breast cancer
37. Estrogen receptor protein in breast cancer as a predictor of recurrence
38. Oestrogen and progesteron receptors as prognostic variables in hormonally treated breast cancer
39. Prognostic value of steroid receptors after long term follow-up of 2257 operable breast cancers
40. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta
41. Angiogenesis assessed by platelet 1 endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
42. Angiogenesis in breast cancer
43. Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer
44. Is the relationship between angiogenesis and metastasis in breast cancer real?
45. Angiogenesis as a predictor of long-term survival for patients wit node-negative breast cancer
46. Angiogenesis and risk of breast cancer in women with fibrocystic disease
47. Angiogenesis and breast cancer metastasis
48. Breast cancer angiogenesis: Therapy target and prognostic factor
49. Development of angiogenesis inhibitors for cancer therapy
50. Clinical significance of angiogenic factors in breast cancer
51. Correlation between tumoral vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma
52. Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis
53. Natural history of node negative breast cancer: A study of 826 patients with long term follow-up
54. Natural history of breast cancer; the curability of small cancers with a limited number of positive nodes
55. Clinical progression of breast cancer malignant behaviour: What to expect and when to expect it